Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
Yahoo · 10 de sept de 2026
Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls
CEDEAR AMGN
Amgen Inc.
Sí, existe CEDEAR de AMGN en Argentina. Operás bajo el ticker AMGN en BYMA, con ratio 30:1 respecto a la acción en NASDAQ.
Empresa subyacente
HealthcareDrug Manufacturers - General
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
- País
- United States
- Empleados
- 31.500
- Sitio web
- amgen.com
Precio histórico
Últimos 200 días · 12/11/25 — 09/09/26
+25.83%
Cotización y datos
NASDAQRatio 30:1 · Subyacente AMGN
CEDEAR (ARS)
Precio
$ 20.380
Var. %
-2,11%
Volumen operado
626
Subyacente (USD)
Precio AMGN
US$ 382,85
Teórico (precio / ratio)
AMGN ÷ 30
US$ 12,76
Dólar MEP (AMGND)
Preguntas frecuentes
¿Existe CEDEAR de AMGN en Argentina?
Sí, existe el CEDEAR de AMGN (Amgen Inc.) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es AMGN.
¿Cuál es el ticker del CEDEAR de Amgen Inc.?
El ticker del CEDEAR de Amgen Inc. en Argentina es AMGN. La acción subyacente cotiza en NASDAQ con el símbolo AMGN.
¿Cuál es el ratio del CEDEAR AMGN?
El CEDEAR AMGN tiene un ratio de 30:1. Eso significa que 30 CEDEARs equivalen a 1 acción de AMGN.
¿Cuánto vale el CEDEAR AMGN hoy?
El CEDEAR AMGN cotiza hoy a $ 20.380 en pesos argentinos, con una variación diaria de -2,11%.
¿Cuánto vale la acción AMGN en dólares?
La acción subyacente AMGN (Amgen Inc.) cotiza a US$ 382,85 en su mercado de origen (NASDAQ).
Noticias
Here Are Thursday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, Amgen, AngloGold Ashanti, Caterpillar, Chewy, Meta Platforms, Novartis, NVIDIA, SK hynix, and More
Yahoo · 10 de sept de 2026
Markets are taking a beating as crude oil surges past $100 and Treasury yields hit multi-year highs, setting up a make-or-break inflation report that could seal…
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review
Yahoo · 10 de sept de 2026
Investing.com -- HSBC adjusted ratings and target prices across its biopharma coverage, citing "a lower sector additional risk premium" following a rally in the…
